Screener
Immix Biopharma, Inc. IMMX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $79,250,163 | $93,928,566 |
| Short-term investments | 11,328,999 | 6,480,860 |
| Prepaid expenses and other current assets | 1,695,649 | 828,329 |
| Total current assets | 92,274,811 | 101,237,755 |
| Other assets | 20,418 | 20,418 |
| Deferred offering costs | 164,723 | 93,630 |
Document
FAQ
- What is Immix Biopharma, Inc.'s short-term investments?
- Immix Biopharma, Inc. (IMMX) reported short-term investments of $11.33M in Q1 2026.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Immix Biopharma, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude